S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NYSE:ALVO

Alvotech (ALVO) Stock Forecast, Price & News

$8.88
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$8.83
▼
$8.99
50-Day Range
$8.76
▼
$10.07
52-Week Range
$5.52
▼
$14.60
Volume
7,039 shs
Average Volume
34,037 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media

Alvotech MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.4% Upside
$9.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Alvotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.64) to ($0.62) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.76 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ALVO stock logo

About Alvotech (NYSE:ALVO) Stock

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

ALVO Price History

ALVO Stock News Headlines

September 23, 2023 | americanbankingnews.com
Alvotech (NYSE:ALVO) Research Coverage Started at Barclays
September 22, 2023 | msn.com
Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate
September 24, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
September 20, 2023 | finance.yahoo.com
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023 | americanbankingnews.com
Contrasting Alvotech (NYSE:ALVO) and Coherus BioSciences (NASDAQ:CHRS)
September 14, 2023 | americanbankingnews.com
Alvotech (NYSE:ALVO) Shares Down 5.1%
September 11, 2023 | finance.yahoo.com
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 5, 2023 | finance.yahoo.com
Alvotech Announces Changes to the Leadership Team
September 24, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
September 3, 2023 | finance.yahoo.com
Need To Know: Analysts Just Made A Substantial Cut To Their Alvotech (NASDAQ:ALVO) Estimates
September 2, 2023 | msn.com
Alvotech: FDA Overhang Remains, Remaining Constructive, Initiate Hold
August 30, 2023 | finance.yahoo.com
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023 | msn.com
Alvotech and Bioventure gain approval for Humira biosimilar in Egypt
August 29, 2023 | finance.yahoo.com
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
August 22, 2023 | finance.yahoo.com
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 7, 2023 | fool.com
Alvotech (NASDAQ: ALVO)
August 2, 2023 | msn.com
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
July 31, 2023 | finance.yahoo.com
Alvotech Completes $100 Million Convertible Bond Private Placement
July 30, 2023 | finance.yahoo.com
Private companies own 34% of Alvotech (NASDAQ:ALVO) shares but private equity firms control 38% of the company
July 24, 2023 | msn.com
Teva Pharmaceuticals and Alvotech expand biosimilars partnership
July 24, 2023 | markets.businessinsider.com
Teva, Alvotech Announce Expanded Strategic Partnership For Biosimilars
July 24, 2023 | finance.yahoo.com
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 9, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech SA - ALVO
July 6, 2023 | msn.com
Alvotech (ALVO) Price Target Increased by 20.00% to 11.02
July 6, 2023 | finance.yahoo.com
Should You Exit Alvotech (ALVO)?
July 3, 2023 | finance.yahoo.com
Alvotech (NASDAQ:ALVO) shareholders have endured a 19% loss from investing in the stock a year ago
July 3, 2023 | marketwatch.com
Alvotech Shares Rebound 20% After FDA Letter Selloff
See More Headlines
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

ALVO Company Calendar

Last Earnings
8/30/2023
Today
9/24/2023
Next Earnings (Estimated)
11/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ALVO
CUSIP
N/A
CIK
1898416
Web
www.alvotech.com
Phone
354-422-4500
Fax
N/A
Employees
917
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+1.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.96
Quick Ratio
0.60

Sales & Book Value

Annual Sales
$85.02 million
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.34) per share
Price / Book
-2.05

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.09
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Robert Wessman (Age 53)
    CEO, Founder & Exec. Chairman
  • Mr. Joel Morales (Age 45)
    Chief Financial Officer
  • Dr. Hafrun Fridriksdottir Ph.D. (Age 61)
    Chief Operating Officer
  • Mr. Giedrius Zunda
    Chief Technical Officer
  • Mr. Joseph E. McClellan (Age 49)
    Chief Scientific Officer
  • Ms. Rose-Marie Ohlsson
    Chief Information Officer
  • Ms. Tanya Zharov (Age 56)
    Gen. Counsel
  • Ms. Eva Yr Gunnlaugsdottir
    VP of People & Culture
  • Mr. Anil Okay (Age 37)
    Chief Commercial Officer
  • Mr. Ming Li (Age 46)
    Chief Strategy Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ALVO Stock - Frequently Asked Questions

Should I buy or sell Alvotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alvotech in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALVO, but not buy additional shares or sell existing shares.
View ALVO analyst ratings or view top-rated stocks.

What is Alvotech's stock price forecast for 2023?

2 brokerages have issued 12-month price targets for Alvotech's shares. Their ALVO share price forecasts range from $8.00 to $10.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for ALVO or view top-rated stocks among Wall Street analysts.

How have ALVO shares performed in 2023?

Alvotech's stock was trading at $10.00 at the start of the year. Since then, ALVO stock has decreased by 11.2% and is now trading at $8.88.
View the best growth stocks for 2023 here.

When is Alvotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 29th 2023.
View our ALVO earnings forecast.

How were Alvotech's earnings last quarter?

Alvotech (NYSE:ALVO) issued its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.29. The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $41.87 million.

What is Alvotech's stock symbol?

Alvotech trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALVO."

Who are Alvotech's major shareholders?

Alvotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (0.00%), Geode Capital Management LLC (0.00%), B. Riley Wealth Advisors Inc. (0.00%) and Wolverine Asset Management LLC (0.00%).

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alvotech's stock price today?

One share of ALVO stock can currently be purchased for approximately $8.88.

How many employees does Alvotech have?

The company employs 917 workers across the globe.

How can I contact Alvotech?

Alvotech's mailing address is 333 SOUTH GRAND AVENUE 28TH FLOOR, LOS ANGELES CA, 90071. The official website for the company is www.alvotech.com. The company can be reached via phone at 354-422-4500 or via email at alvotech.ir@alvotech.com.

This page (NYSE:ALVO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -